IP Library Patent Application 17156824
Patent Application
App. No. 17/156,824

SELF-MICELLIZING FATTY ACIDS AND FATTY ACID ESTER COMPOSITIONS AND THEIR USE IN THE TREATMENT OF DISEASE STATES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/156,824
Abstract

Described herein are compositions including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided are methods of administering to a subject a composition including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent, wherein the compositions form micelles when in contact with an aqueous medium, and the bioavailability of the omega-3 fatty acid is substantially independent of a food effect. The compositions are useful for treating certain disease states which may include (1) malabsorption syndromes, (2) primary sclerosing cholangitis (PSC), (3) non-alcoholic fatty liver disease (NAFLD), (4) sickle cell disease (SCD), (5) age-related macular degeneration (AMD), and (6) neurodegenerative disease, including, Parkinson's Disease (PD), Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Epilepsy, Bi-polar Syndrome, traumatic brain injury, peripheral neuropathy, and Multiple Sclerosis (MS). Described are also various dosage forms for administering the compositions and use of the compositions in functional foods. Provided herein are also kits with instructions for their administration.

Claims (6)

1 . A pharmaceutical composition comprising at least one omega-3 fatty acid and at least one surface active agent,

wherein said at least one surface active agent comprises a combination of at least one polysorbate and at least one poloxamer,

wherein said at least one polysorbate comprises from about 30.0% wt/wt to about 32.0% wt/wt of said composition,

wherein said at least one poloxamer comprises from about 0.60% wt/wt to about 0.80% wt/wt of said composition,

wherein said at least one polysorbate is polysorbate 80, and

wherein said at least one poloxamer is poloxamer 237.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2022
From: OMEGA BIOPHARMA, INC.; MICELLE BIOPHARMA, INC.
To: GENERX, INC.
Reel/Frame 059832/0062 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2021
From: SANCILIO, FREDERICK; THORSTEINSSON, THORSTEINN; DANIEL-ARCHIBALD, GLYNIS; LOPEZ-TOLEDANO, MIGUEL; MOHAMMED DAAK, AHMED ABD ALMALIK AHMED
To: SANCILIO & COMPANY, INC.
Reel/Frame 055018/0730 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2021
From: SANCILIO & COMPANY, INC.
To: MICELLE BIOPHARMA, INC.
Reel/Frame 055096/0151 →